SPDR S&P Biotech Stock Price, News & Analysis (NYSEARCA:XBI)

$88.02 1.18 (1.36 %)
(As of 01/17/2018 04:00 PM ET)
Previous Close$86.84
Today's Range$87.05 - $88.33
52-Week Range$61.14 - $90.33
Volume6.47 million shs
Average Volume5.59 million shs
Market Capitalization$4.65 billion
P/E Ratio4.83
Dividend Yield0.23%
BetaN/A

About SPDR S&P Biotech (NYSEARCA:XBI)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

Receive XBI News and Ratings via Email

Sign-up to receive the latest news and ratings for XBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Investment Trusts
Sub-IndustryN/A
SectorFinancials
SymbolNYSEARCA:XBI
CUSIPN/A
Phone+1-866-7872257

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio4.8283049917718
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$18.23
Net IncomeN/A
Net Margins3,150.61%
Return on Equity40.83%
Return on Assets32.53%

Miscellaneous

EmployeesN/A
Outstanding Shares53,100,000

SPDR S&P Biotech (NYSEARCA:XBI) Frequently Asked Questions

What is SPDR S&P Biotech's stock symbol?

SPDR S&P Biotech trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

How often does SPDR S&P Biotech pay dividends? What is the dividend yield for SPDR S&P Biotech?

SPDR S&P Biotech declared a quarterly dividend on Monday, December 18th. Investors of record on Monday, December 18th will be paid a dividend of $0.0347 per share on Tuesday, December 26th. This represents a $0.14 annualized dividend and a yield of 0.16%. The ex-dividend date is Friday, December 15th. View SPDR S&P Biotech's Dividend History.

Are investors shorting SPDR S&P Biotech?

SPDR S&P Biotech saw a increase in short interest in the month of December. As of December 29th, there was short interest totalling 27,031,163 shares, an increase of 9.0% from the December 15th total of 24,789,533 shares. Based on an average daily trading volume, of 3,189,981 shares, the days-to-cover ratio is currently 8.5 days.

Who are some of SPDR S&P Biotech's key competitors?

Who are SPDR S&P Biotech's key executives?

SPDR S&P Biotech's management team includes the folowing people:

  • James E. Ross, President, Trustee (Age 52)
  • Peter A. Ambrosini, Chief Compliance Officer (Age 69)
  • Michael P. Riley, Vice President (Age 44)
  • Gary L. French, Treasurer (Age 64)
  • John W. Clark, Assistant Treasurer (Age 46)
  • Matthew W. Flaherty, Assistant Treasurer (Age 42)
  • Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)
  • Mary Moran Zeven, Secretary (Age 52)
  • Scott M. Zoltowski, Assistant Secretary (Age 44)
  • Dave Kelly, Independent Trustee

Who owns SPDR S&P Biotech stock?

SPDR S&P Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.38%), Cumberland Advisors Inc. (0.08%), Perkins Coie Trust Co (0.06%), Creative Planning (0.06%), Ayalon Holdings Ltd. (0.03%) and Private Capital Advisors Inc. (0.03%). View Institutional Ownership Trends for SPDR S&P Biotech.

Who sold SPDR S&P Biotech stock? Who is selling SPDR S&P Biotech stock?

SPDR S&P Biotech's stock was sold by a variety of institutional investors in the last quarter, including Perkins Coie Trust Co. View Insider Buying and Selling for SPDR S&P Biotech.

Who bought SPDR S&P Biotech stock? Who is buying SPDR S&P Biotech stock?

SPDR S&P Biotech's stock was bought by a variety of institutional investors in the last quarter, including Cumberland Advisors Inc., Creative Planning, Ayalon Holdings Ltd., Private Capital Advisors Inc., Bank of Montreal Can, Covenant Asset Management LLC and Train Babcock Advisors LLC. View Insider Buying and Selling for SPDR S&P Biotech.

How do I buy SPDR S&P Biotech stock?

Shares of SPDR S&P Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SPDR S&P Biotech's stock price today?

One share of SPDR S&P Biotech stock can currently be purchased for approximately $88.02.

How big of a company is SPDR S&P Biotech?

SPDR S&P Biotech has a market capitalization of $4.65 billion.

How can I contact SPDR S&P Biotech?

SPDR S&P Biotech's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.


MarketBeat Community Rating for SPDR S&P Biotech (XBI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about SPDR S&P Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Show:

Dividends

SPDR S&P Biotech (NYSEARCA:XBI) Dividend Information

Most Recent Dividend:12/26/2017
Annual Dividend:$0.20
Dividend Yield:0.23%
Payout Ratio:1.10% (Trailing 12 Months of Earnings)
Dividend Payments by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

SPDR S&P Biotech (NYSEARCA:XBI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/18/2017quarterly$0.030.17%12/15/201712/18/201712/26/2017
9/15/2017quarterly$0.040.18%9/15/20179/18/20179/25/2017
6/16/2017quarterly$0.110.62%6/16/20176/20/20176/26/2017
3/17/2017quarterly$0.020.11%3/17/20173/21/20173/27/2017
12/16/2016quarterly$0.020.12%12/16/201612/20/201612/27/2016
6/19/2015quarterly$0.440.69%6/19/20156/23/20156/29/2015
3/20/2015quarterly$0.250.42%3/20/20153/24/20153/30/2015
12/19/2014quarterly$0.491.03%12/19/201412/23/201412/30/2014
9/19/2014quarterly$0.561.42%9/19/20149/23/20149/29/2014
6/20/2014quarterly$0.621.61%6/20/20146/24/20146/30/2014
3/21/2014quarterly$0.330.87%3/21/20143/25/20143/31/2014
12/20/2013quarterly$0.040.12%12/20/201312/24/201312/31/2013
9/20/2013quarterly$0.090.27%9/20/20139/24/20139/30/2013
3/15/2013quarterly$0.040.18%3/15/20133/19/20133/25/2013
12/21/2012quarterly$0.200.89%12/21/201212/26/20121/4/2013
(Data available from 1/1/2013 forward)

Headlines

SPDR S&P Biotech (NYSEARCA XBI) News Headlines

Source:
DateHeadline
Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to RockBest ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock
finance.yahoo.com - January 17 at 10:27 AM
SPDR S&P Biotech (XBI) Short Interest Up 9.0% in DecemberSPDR S&P Biotech (XBI) Short Interest Up 9.0% in December
www.americanbankingnews.com - January 16 at 3:32 AM
That Biotech M&A Wave? More like a Trickle - BarronsThat Biotech M&A Wave? More like a Trickle - Barron's
www.barrons.com - January 13 at 4:15 PM
4 Small-Cap Biotechs With Near-Term Trading Catalysts - Seeking Alpha4 Small-Cap Biotechs With Near-Term Trading Catalysts - Seeking Alpha
seekingalpha.com - January 12 at 4:17 PM
PTLA Crosses Above Key Moving Average LevelPTLA Crosses Above Key Moving Average Level
www.nasdaq.com - January 9 at 4:27 PM
Dan Nathan Sees Unusual Options Activity In XBIDan Nathan Sees Unusual Options Activity In XBI
www.benzinga.com - January 9 at 10:26 AM
Mondays ETF Movers: FXL, XBIMonday's ETF Movers: FXL, XBI
www.nasdaq.com - January 8 at 4:30 PM
Rush for Marijuana ETFs Getting Stronger - NasdaqRush for Marijuana ETFs Getting Stronger - Nasdaq
www.nasdaq.com - December 28 at 3:21 PM
Wednesdays ETF Movers: XBI, XRTWednesday's ETF Movers: XBI, XRT
www.nasdaq.com - December 27 at 6:36 PM
Shipwreck? Biotechs Lightweight CEOs Add to 2018 ChallengesShipwreck? Biotech's Lightweight CEOs Add to 2018 Challenges
finance.yahoo.com - December 27 at 6:36 PM
Top-Ranked ETFs & Stocks That Crushed the Market in 2017Top-Ranked ETFs & Stocks That Crushed the Market in 2017
www.zacks.com - December 26 at 10:21 AM
Small Is Best for Biotech ETFsSmall Is Best for Biotech ETFs
www.msn.com - December 23 at 4:39 AM
Top Sector ETFs of 2017 - NasdaqTop Sector ETFs of 2017 - Nasdaq
www.nasdaq.com - December 22 at 11:39 PM
The Companies That Led 2017s Biotech Rally - BenzingaThe Companies That Led 2017's Biotech Rally - Benzinga
www.benzinga.com - December 22 at 11:39 PM
Cell, Not Sell: Be in Biotech in 2018Cell, Not Sell: Be in Biotech in 2018
finance.yahoo.com - December 21 at 4:27 PM
Gilead: Maybe 2018 Wont Be Its Year Either - NasdaqGilead: Maybe 2018 Won't Be Its Year Either - Nasdaq
www.nasdaq.com - December 21 at 10:32 AM
5 Biotech Picks for 20185 Biotech Picks for 2018
www.msn.com - December 19 at 10:36 AM
5 Biotech Stocks a Pro Is Buying5 Biotech Stocks a Pro Is Buying
www.barrons.com - December 19 at 10:36 AM
SPDR S&P Biotech ETF Plans Quarterly Dividend of $0.03 (XBI)SPDR S&P Biotech ETF Plans Quarterly Dividend of $0.03 (XBI)
www.americanbankingnews.com - December 18 at 10:28 PM
The 3 Best Biotech Stocks of 2017 - Motley FoolThe 3 Best Biotech Stocks of 2017 - Motley Fool
www.fool.com - December 18 at 10:59 AM
Biotech: No Happy New Year?Biotech: No Happy New Year?
finance.yahoo.com - December 18 at 10:59 AM
SPDR S&P Biotech ETF (XBI) Short Interest Up 14.3% in NovemberSPDR S&P Biotech ETF (XBI) Short Interest Up 14.3% in November
www.americanbankingnews.com - December 17 at 2:04 AM
How to trade biotech: 3 playsHow to trade biotech: 3 plays
finance.yahoo.com - December 15 at 11:00 AM
Biotech: Lean in on the PullbackBiotech: Lean in on the Pullback
finance.yahoo.com - December 15 at 11:00 AM
Gilead: The Follower Becomes the Leader? - BarronsGilead: The Follower Becomes the Leader? - Barron's
www.barrons.com - December 13 at 4:34 PM
For the Love of Biotech, Know What You OwnFor the Love of Biotech, Know What You Own
finance.yahoo.com - December 12 at 10:59 AM
Glaxo Who? Why Gileads HIV Drug Could Be the Greatest of All Time - BarronsGlaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time' - Barron's
www.barrons.com - December 8 at 10:38 AM
Thursdays ETF Movers: XBI, ILF - NasdaqThursday's ETF Movers: XBI, ILF - Nasdaq
www.nasdaq.com - December 7 at 4:39 PM
How Biotechs, Drugmakers Would Fare Under The Senate's Tax BillHow Biotechs, Drugmakers Would Fare Under The Senate's Tax Bill
finance.yahoo.com - December 5 at 12:17 PM
Biotech Slump Could be a Buying OpportunityBiotech Slump Could be a Buying Opportunity
finance.yahoo.com - December 5 at 12:17 PM
Biotech: You Really, Really Dont Like MeBiotech: You Really, Really Don't Like Me
finance.yahoo.com - December 1 at 5:48 PM
Biotech Poised for Growth: 3 Healthy Fund ChoicesBiotech Poised for Growth: 3 Healthy Fund Choices
www.zacks.com - November 24 at 8:16 AM
Analysts Forecast 35% Gains Ahead For The Holdings Of XBIAnalysts Forecast 35% Gains Ahead For The Holdings Of XBI
www.thestreet.com - November 23 at 7:09 AM
Biotech: What You Dont Know…And What You Dont Know You Dont Know…Could Hurt YouBiotech: What You Don't Know…And What You Don't Know You Don't Know…Could Hurt You
finance.yahoo.com - November 20 at 4:16 PM
Easy Come, Easy Go: Biotechs Fading Flows - BarronsEasy Come, Easy Go: Biotech's Fading Flows - Barron's
www.barrons.com - November 19 at 10:36 AM
Easy Come, Easy Go: Biotech’s Fading FlowsEasy Come, Easy Go: Biotech’s Fading Flows
www.msn.com - November 18 at 10:26 AM
Biotech Decline Could be a Buying OpportunityBiotech Decline Could be a Buying Opportunity
finance.yahoo.com - November 18 at 10:26 AM
Easy Come, Easy Go: Biotechs Fading FlowsEasy Come, Easy Go: Biotech's Fading Flows
finance.yahoo.com - November 18 at 10:26 AM
Tuesdays ETF Movers: IDU, XBI - NasdaqTuesday's ETF Movers: IDU, XBI - Nasdaq
www.nasdaq.com - November 16 at 8:57 AM
Top 3 Healthcare ETFs for 2017Top 3 Healthcare ETFs for 2017
finance.yahoo.com - November 16 at 8:57 AM
Biotech ETFs: What Lies Ahead?Biotech ETFs: What Lies Ahead?
www.nasdaq.com - November 13 at 8:11 PM
Implied XBI Analyst Target Price: $110Implied XBI Analyst Target Price: $110
www.thestreet.com - November 13 at 8:11 PM
Biotech: Go With the Flow - Barrons - BarronsBiotech: Go With the Flow - Barron's - Barron's
www.barrons.com - November 12 at 6:36 PM
Biotech: Go With the FlowBiotech: Go With the Flow
finance.yahoo.com - November 12 at 1:35 PM
Noteworthy ETF Inflows: XBI, ALNY, PBYI, SGEN - Nasdaq.com - NasdaqNoteworthy ETF Inflows: XBI, ALNY, PBYI, SGEN - Nasdaq.com - Nasdaq
www.nasdaq.com - November 8 at 12:17 AM
Pfizer Inc. Stock Is Boring, and That’s PerfectPfizer Inc. Stock Is Boring, and That’s Perfect
finance.yahoo.com - October 31 at 12:31 PM
Biotech in the Bargain Bin - BarronsBiotech in the Bargain Bin - Barron's
www.barrons.com - October 29 at 9:17 AM
The Biotech Blues: Gileads Earnings Another Sour Note in a Week Full of Them - BarronsThe Biotech Blues: Gilead's Earnings Another Sour Note in a Week Full of Them - Barron's
www.barrons.com - October 29 at 9:17 AM
Its A Bad Day For Biotechs - BenzingaIt's A Bad Day For Biotechs - Benzinga
www.benzinga.com - October 27 at 7:43 AM
XBI Crosses Critical Technical Indicator - NasdaqXBI Crosses Critical Technical Indicator - Nasdaq
www.nasdaq.com - October 27 at 7:43 AM

SEC Filings

SPDR S&P Biotech (NYSEARCA:XBI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

SPDR S&P Biotech (NYSEARCA XBI) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.